Which has preferable earnings and valuation, BDSX or ITGR?

Integer has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 1.87 -$35.26M -$4.06 N/A Integer $1.85B 1.65 $102.81M $4.01 22.48

Is BDSX or ITGR more profitable?

Integer has a net margin of 7.64% compared to Biodesix's net margin of -33.26%. Integer's return on equity of 12.83% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -33.26% -2,101.40% -35.65% Integer 7.64% 12.83% 6.51%

Does the media favor BDSX or ITGR?

In the previous week, Integer had 18 more articles in the media than Biodesix. MarketBeat recorded 20 mentions for Integer and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.55 beat Integer's score of 0.04 indicating that Biodesix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Integer 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ITGR or ELV?

Elevance Health has higher revenue and earnings than Integer. Elevance Health is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 1.65 $102.81M $4.01 22.48 Elevance Health $199.13B 0.43 $5.66B $23.51 16.74

Does the media refer more to ITGR or ELV?

In the previous week, Integer had 10 more articles in the media than Elevance Health. MarketBeat recorded 20 mentions for Integer and 10 mentions for Elevance Health. Elevance Health's average media sentiment score of 1.22 beat Integer's score of 0.04 indicating that Elevance Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Elevance Health 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ITGR or GMED?

Globus Medical has higher revenue and earnings than Integer. Globus Medical is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 1.65 $102.81M $4.01 22.48 Globus Medical $2.94B 3.79 $537.87M $4.30 19.07

Is ITGR or GMED more profitable?

Globus Medical has a net margin of 18.92% compared to Integer's net margin of 7.64%. Globus Medical's return on equity of 13.46% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 7.64% 12.83% 6.51% Globus Medical 18.92% 13.46% 11.65%

Does the media refer more to ITGR or GMED?

In the previous week, Integer had 4 more articles in the media than Globus Medical. MarketBeat recorded 20 mentions for Integer and 16 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.65 beat Integer's score of 0.04 indicating that Globus Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Globus Medical 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ITGR or PODD?

Insulet has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 1.65 $102.81M $4.01 22.48 Insulet $2.71B 3.65 $247.10M $4.30 33.17

Is ITGR or PODD more profitable?

Insulet has a net margin of 10.44% compared to Integer's net margin of 7.64%. Insulet's return on equity of 26.87% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 7.64% 12.83% 6.51% Insulet 10.44% 26.87% 12.01%

Does the media prefer ITGR or PODD?

In the previous week, Integer and Integer both had 20 articles in the media. Insulet's average media sentiment score of 0.13 beat Integer's score of 0.04 indicating that Insulet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Insulet 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ITGR or MASI?

Integer has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 1.65 $102.81M $4.01 22.48 Masimo $1.53B 6.12 -$151.50M -$10.54 N/A

Is ITGR or MASI more profitable?

Integer has a net margin of 7.64% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 7.64% 12.83% 6.51% Masimo 4.90% 31.33% 13.93%

Does the media refer more to ITGR or MASI?

In the previous week, Integer had 17 more articles in the media than Masimo. MarketBeat recorded 20 mentions for Integer and 3 mentions for Masimo. Masimo's average media sentiment score of 0.82 beat Integer's score of 0.04 indicating that Masimo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Masimo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Integer (ITGR) Competitors

$90.16 +0.11 (+0.12%)

As of 01:26 PM Eastern

Compare

ITGR vs. BDSX, ELV, GMED, PODD, and MASI

Should you buy Integer stock or one of its competitors? MarketBeat compares Integer with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Integer include Biodesix (BDSX), Elevance Health (ELV), Globus Medical (GMED), Insulet (PODD), and Masimo (MASI). These companies are all part of the "medical" sector.

How does Integer compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Integer (NYSE:ITGR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Integer has a net margin of 7.64% compared to Biodesix's net margin of -33.26%. Integer's return on equity of 12.83% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Integer	7.64%	12.83%	6.51%

21.0% of Biodesix shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 1.1% of Integer shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biodesix presently has a consensus target price of $22.00, indicating a potential upside of 37.45%. Integer has a consensus target price of $98.71, indicating a potential upside of 9.49%. Given Biodesix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Biodesix is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Integer has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	1.87	-$35.26M	-$4.06	N/A
Integer	$1.85B	1.65	$102.81M	$4.01	22.48

In the previous week, Integer had 18 more articles in the media than Biodesix. MarketBeat recorded 20 mentions for Integer and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.55 beat Integer's score of 0.04 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Integer	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biodesix has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Integer has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Summary

Integer beats Biodesix on 11 of the 16 factors compared between the two stocks.

How does Integer compare to Elevance Health?

Integer (NYSE:ITGR) and Elevance Health (NYSE:ELV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Integer presently has a consensus price target of $98.71, indicating a potential upside of 9.49%. Elevance Health has a consensus price target of $403.11, indicating a potential upside of 2.40%. Given Integer's higher possible upside, research analysts plainly believe Integer is more favorable than Elevance Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Elevance Health	0 Sell rating(s)	9 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.61

In the previous week, Integer had 10 more articles in the media than Elevance Health. MarketBeat recorded 20 mentions for Integer and 10 mentions for Elevance Health. Elevance Health's average media sentiment score of 1.22 beat Integer's score of 0.04 indicating that Elevance Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elevance Health	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of Integer shares are owned by institutional investors. Comparatively, 89.2% of Elevance Health shares are owned by institutional investors. 1.1% of Integer shares are owned by company insiders. Comparatively, 0.3% of Elevance Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Elevance Health has higher revenue and earnings than Integer. Elevance Health is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.65	$102.81M	$4.01	22.48
Elevance Health	$199.13B	0.43	$5.66B	$23.51	16.74

Integer has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Elevance Health has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Integer has a net margin of 7.64% compared to Elevance Health's net margin of 2.62%. Elevance Health's return on equity of 15.58% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
Elevance Health	2.62%	15.58%	5.57%

Summary

Integer beats Elevance Health on 9 of the 16 factors compared between the two stocks.

How does Integer compare to Globus Medical?

Integer (NYSE:ITGR) and Globus Medical (NYSE:GMED) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Integer currently has a consensus price target of $98.71, suggesting a potential upside of 9.49%. Globus Medical has a consensus price target of $106.36, suggesting a potential upside of 29.73%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts clearly believe Globus Medical is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87

In the previous week, Integer had 4 more articles in the media than Globus Medical. MarketBeat recorded 20 mentions for Integer and 16 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.65 beat Integer's score of 0.04 indicating that Globus Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Globus Medical	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of Integer shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 1.1% of Integer shares are owned by company insiders. Comparatively, 18.4% of Globus Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Globus Medical has higher revenue and earnings than Integer. Globus Medical is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.65	$102.81M	$4.01	22.48
Globus Medical	$2.94B	3.79	$537.87M	$4.30	19.07

Integer has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Globus Medical has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Globus Medical has a net margin of 18.92% compared to Integer's net margin of 7.64%. Globus Medical's return on equity of 13.46% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
Globus Medical	18.92%	13.46%	11.65%

Summary

Globus Medical beats Integer on 14 of the 17 factors compared between the two stocks.

How does Integer compare to Insulet?

Integer (NYSE:ITGR) and Insulet (NASDAQ:PODD) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Integer has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Insulet has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

99.3% of Integer shares are held by institutional investors. 1.1% of Integer shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Insulet has a net margin of 10.44% compared to Integer's net margin of 7.64%. Insulet's return on equity of 26.87% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
Insulet	10.44%	26.87%	12.01%

Insulet has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.65	$102.81M	$4.01	22.48
Insulet	$2.71B	3.65	$247.10M	$4.30	33.17

Integer currently has a consensus price target of $98.71, suggesting a potential upside of 9.49%. Insulet has a consensus price target of $252.04, suggesting a potential upside of 76.70%. Given Insulet's stronger consensus rating and higher probable upside, analysts clearly believe Insulet is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74

In the previous week, Integer and Integer both had 20 articles in the media. Insulet's average media sentiment score of 0.13 beat Integer's score of 0.04 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insulet	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Insulet beats Integer on 13 of the 15 factors compared between the two stocks.

How does Integer compare to Masimo?

Integer (NYSE:ITGR) and Masimo (NASDAQ:MASI) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Integer has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Masimo has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

99.3% of Integer shares are held by institutional investors. Comparatively, 86.0% of Masimo shares are held by institutional investors. 1.1% of Integer shares are held by insiders. Comparatively, 9.7% of Masimo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Integer has a net margin of 7.64% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
Masimo	4.90%	31.33%	13.93%

Integer currently has a consensus target price of $98.71, indicating a potential upside of 9.49%. Masimo has a consensus target price of $180.40, indicating a potential upside of 1.09%. Given Integer's stronger consensus rating and higher probable upside, research analysts clearly believe Integer is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Integer had 17 more articles in the media than Masimo. MarketBeat recorded 20 mentions for Integer and 3 mentions for Masimo. Masimo's average media sentiment score of 0.82 beat Integer's score of 0.04 indicating that Masimo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Masimo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Integer has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.65	$102.81M	$4.01	22.48
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A

Summary

Integer beats Masimo on 10 of the 16 factors compared between the two stocks.

Get Integer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ITGR vs. The Competition

Export

Metric	Integer	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$3.06B	$7.15B	$6.42B	$23.17B
Dividend Yield	N/A	1.32%	2.75%	4.07%
P/E Ratio	22.48	45.41	21.28	30.90
Price / Sales	1.65	73.95	558.91	24.62
Price / Cash	8.58	24.64	43.49	24.96
Price / Book	1.80	7.32	10.60	4.81
Net Income	$102.81M	$158.10M	$3.56B	$1.07B
7 Day Performance	0.92%	10.29%	3.21%	1.35%
1 Month Performance	7.87%	13.09%	6.51%	3.19%
1 Year Performance	-24.54%	4.15%	36.74%	27.60%

Integer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITGR Integer	2.1576 of 5 stars	$90.16 +0.1%	$98.71 +9.5%	-24.7%	$3.06B	$1.85B	22.48	11,000	Analyst Forecast Analyst Revision
BDSX Biodesix	3.7243 of 5 stars	$14.25 +0.6%	$31.00 +117.5%	+133.0%	$143.24M	$88.50M	N/A	220	Positive News
ELV Elevance Health	4.4481 of 5 stars	$393.35 +0.2%	$384.58 -2.2%	+3.9%	$85.28B	$199.13B	16.73	97,100	Positive News Analyst Forecast
GMED Globus Medical	4.4109 of 5 stars	$78.95 +3.0%	$106.36 +34.7%	+39.7%	$10.40B	$2.94B	18.36	6,000	Analyst Revision
PODD Insulet	4.2891 of 5 stars	$152.49 +3.4%	$254.96 +67.2%	-55.9%	$10.21B	$2.71B	35.46	5,400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ITGR) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Integer (ITGR) Competitors